Scott Alexander McDonald
Datos Biográficos
| ID | 10031991 |
|---|---|
| NOMBRE | Scott Alexander McDonald |
| NOMBRES | Scott Alexander |
| APELLIDO | McDonald |
| FIRMA | MCDONALD S A |
| VERIFICADO | No |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2023 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2023 |
| ÍNDICE H | 0 |
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
Introduction: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has highe…
Sin obras prominentes en esta página.
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
Introduction: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has highe…
Daclatasvir (1 obra) · Emergency Medicine (1 obra) · Health Systems, Economic Evaluations, Quality of Life (1 obra) · Hepatitis C virus (1 obra) · Hepatitis C virus research (1 obra) · Internal Medicine (1 obra) · Liver disease (1 obra) · Medicine (1 obra) · Pharmaceutical Economics and Policy (1 obra) · Sofosbuvir (1 obra)